<DOC>
	<DOCNO>NCT01177540</DOCNO>
	<brief_summary>The purpose study provide data activity standard daunorubicin , cytarabine , etoposide ( ADE ) induction plus epigenetic priming decitabine assess standard measure complete remission ( CR ) , leukemia free survival ( LFS ) overall survival ( OS ) , well , minimal residual disease ( MRD ) . It also provide necessary data safety Pharmacokinetics ( PK ) decitabine pediatric patient currently unavailable .</brief_summary>
	<brief_title>Efficacy Safety Decitabine Epigenetic Priming With Induction Chemotherapy Pediatric Acute Myelogenous Leukemia ( AML ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria 1 . Males female , age 1 16 year , inclusive 2 . Females childbearing potential must negative serum beta human chorionic gonadotropin ( BhCG ) Visit 1 ( Screening ) negative urine pregnancy test prior start study drug ( Visit 2 ) . Female subject childbearing potential must agree abstinent use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , intrauterine devise ( IUD ) , vasectomised partner ) least one menstrual cycle prior start study drug ( ) throughout Randomization Phase 30 day last dose study drug . Those female use hormonal contraceptive must also use additional approve method contraception ( describe previously ) 3 . Sexually mature male patient abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug ( ) throughout Randomization Phase 30 day ( longer appropriate ) last dose study drug . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) 4 . Diagnosis acute myelogenous leukemia ( AML ) ( bone marrow peripheral blood blast great equal 20 % ) 5 . Adequate cardiac function define echocardiogram multiple gate acquisition ( MUGA ) scan demonstrate ejection fraction great 50 % 6 . Are willing able comply aspect protocol 7 . Provide write informed consent subject 's guardian legally authorize representative child assent ( applicable ) . Exclusion Criteria 1 . Females pregnant ( positive BhCG test ) lactate 2 . History chronic myelogenous leukemia ( CML ) [ ( 9 ; 22 ) ] 3 . Acute promyelocytic leukemia ( M3 subtype FrenchAmericanBritish [ FAB ] classification ) 4 . Known central nervous system ( CNS ) leukemia 5 . AML associate congenital syndrome Down syndrome , Fanconi anemia , Bloom syndrome , Kostmann syndrome , DiamondBlackfan anemia 6 . White blood cell ( WBC ) count great 100,000/mm3 7 . Serum creatinine great 2.5 mg/dL 8 . Alanine aminotransferase ( ALT ) great 5 x upper limit normal ( ULN ) and/or total bilirubin great 3 x ULN 9 . Prior chemotherapy ( hydroxyurea ) radiation therapy AML 10 . Known human immunodeficiency virus ( HIV ) positive 11 . Any history concomitant medical condition , opinion Investigator , would compromise subject 's ability safely complete study 12 . The Investigator believe subject medically unfit receive study drug unsuitable reason 13 . Subject hypersensitivity decitabine , daunorubicin , cytarabine , etoposide 14 . Has participate drug trial last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>